



BMT CTN 0301

Unrelated BMT for Aplastic Anemia with Reduced Intensity Conditioning


Objective

- Determine feasibility and toxicity of fludarabine-based conditioning
- Reduce toxicity while maintaining or improving engraftment

Eligibility

- Severe Aplastic Anemia (SAA)
- 7/8 or 8/8 HLA matched unrelated donor
- Age \leq 65 years

TREATMENT SCHEMA



*Phase I of study tests each of four total dose levels of CY (150 mg/kg, 100 mg/kg, 50 mg/kg, 0 mg/kg) for adequate safety and graft retention.

*Phase II of study refines dose selection and allocates patients to optimal dose.

Assess for 2 years

To view entire protocol, go to <http://www.bmtctn.net>
or the PDQ website at <http://cancer.gov/clinicaltrials/BMTCTN-0301>

This is a Phase I "dose finding" and Phase II "dose selection refining" multi-center trial
jointly sponsored by the NHLBI and NCI